Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

Asthma/COPD drug PMPM spending U.S. 2018-2023

In 2023, per member per month (PMPM) spending for asthma and COPD (chronic obstructive pulmonary disease) prescription drug is forecasted to be around 2.43 U.S. dollars per member per month in the United States. This statistic illustrates the forecast of asthma prescription drug PMPM spending in the United States from 2018 to 2023.

Asthma and COPD drug PMPM spending in the United States from 2018 to 2023

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until May 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

March 2020

Region

United States

Survey time period

2017 to 2020

Supplementary notes

PMPM: per member per month (spending). Spending includes Medicare, Medicaid, commercial insurance and pipeline drugs.
* Forecast.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Chronic Obstructive Pulmonary Disease (COPD) in the U.S. "

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.